



## **Pertuzumab, Trastuzumab and Hyaluronidase-zzxf (Phesgo™)**

### **IMPORTANT REMINDER**

We develop Medical Policies to provide guidance to Members and Providers. This Medical Policy relates only to the services or supplies described in it. The existence of a Medical Policy is not an authorization, certification, explanation of benefits or a contract for the service (or supply) that is referenced in the Medical Policy. For a determination of the benefits that a Member is entitled to receive under his or her health plan, the Member's health plan must be reviewed. If there is a conflict between the medical policy and a health plan or government program (e.g., TennCare), the express terms of the health plan or government program will govern.

**The proposal is to add text/statements in red and to delete text/statements with strikethrough:  
POLICY**

### **INDICATIONS**

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

#### FDA-Approved Indications

##### Neoadjuvant treatment of breast cancer

For use in combination with chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer.

##### Adjuvant treatment of breast cancer

For use in combination with chemotherapy for the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence.

##### Metastatic breast cancer (MBC)

For use in combination with docetaxel for the treatment of adult patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.

#### Compendial Uses

HER2-positive breast cancer: May be substituted anywhere that the combination of intravenous pertuzumab and intravenous trastuzumab are given as part of systemic therapy.

All other indications are considered experimental/investigational and not medically necessary.

### **DOCUMENTATION**

Submission of the following information is necessary to initiate the prior authorization review: human epidermal growth factor receptor 2 (HER2) status.

### **COVERAGE CRITERIA**

#### **Breast Cancer**

- Authorization of 12 months may be granted for pre-operative (neoadjuvant) treatment of HER2-positive breast cancer in combination with chemotherapy for locally advanced, inflammatory, or early-stage breast cancer ~~(either greater than 2 cm in diameter or node positive).~~

## Medical Policy Manual

## Draft Revision Policy: Do Not Implement

- Authorization of 12 months may be granted for adjuvant treatment of HER2-positive breast cancer for **locally advanced or early stage disease**.
- Authorization of 12 months may be granted for the treatment of HER2-positive recurrent **unresectable** or metastatic breast cancer or HER2-positive breast cancer with no response to preoperative systemic therapy.

### CONTINUATION OF THERAPY

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for an indication listed in the coverage criteria section when there is no evidence of unacceptable toxicity or disease progression while on the current regimen. Adjuvant and neoadjuvant treatment of breast cancer will be approved for a total of 12 months of therapy.

### APPLICABLE TENNESSEE STATE MANDATE REQUIREMENTS

BlueCross BlueShield of Tennessee's Medical Policy complies with Tennessee Code Annotated Section 56-7-2352 regarding coverage of off-label indications of Food and Drug Administration (FDA) approved drugs when the off-label use is recognized in one of the statutorily recognized standard reference compendia or in the published peer-reviewed medical literature.

### ADDITIONAL INFORMATION

For appropriate chemotherapy regimens, dosage information, contraindications, precautions, warnings, and monitoring information, please refer to one of the standard reference compendia (e.g., the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) published by the National Comprehensive Cancer Network®, Drugdex Evaluations of Micromedex Solutions at Truven Health, or The American Hospital Formulary Service Drug Information).

### REFERENCES

1. Phesgo [package insert]. South San Francisco, CA: Genentech, Inc.; November 2024.
2. The NCCN Drugs & Biologics Compendium® © 2025 National Comprehensive Cancer Network, Inc. Available at: <https://www.nccn.org>. Accessed December 8, 2025.
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 5.2025. Available at: [https://www.nccn.org/professionals/physician\\_gls/pdf/breast.pdf](https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf). December 8, 2025.
4. Von Minckwitz, G. et al. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. *N. Engl. J. Med.* 377, 122–131 (2017). Available at: <https://www.nejm.org/doi/full/10.1056/nejmoa1703643>

### EFFECTIVE DATE

ID\_CHS\_2026